| 1 |
|
Value-Based Medtech Rides The Money-Go-Round Into 2016
|
Yeo, Ashley
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 2 |
|
Value-Based Pharma R&D Productivity: Is There A Sweet Spot? What do Gilead, Biogen, and Celgene have in common? Qualities to be the top three drugmakers ranked by both R&D productivity and growth, according to a novel method for measuring such criteria that management consulting firm Catenion says offers insights for achieving such success
|
Thunecke, M.; Scholefield, G.; Meyer, C.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 3 |
|
Value-based pharma R&D productivity: is there a scalable model?
|
Thunecke, Markus
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 4 |
|
Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
|
Thunecke, Markus; Scholefield, Graham
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 5 |
|
Vascular Closure Market Makes Room For Innovative Solutions
|
Charlish, Peter
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 6 |
|
Vascular Interventional Devices: New Avenues For Growth
|
Thompson, M.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 7 |
|
Vascular Solutions Case May Point Way Forward For Off-Label Marketing
|
Orr, Elizabeth
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 8 |
|
Veracyte: How To Build A Molecular Cytology Company
|
Ratner, M.L.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 9 |
|
Virtually all the companies that made it big historically, made it on their own. You think of Genzyme, you think of BioMarin, you think of ViroPharma: they were the masters of their own destiny and it worked very well for them
|
Nader, F.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 10 |
|
Vivo Ventures' Time Arrives As All Eyes Look To China
|
Salemi, T.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 11 |
|
Volcano: Learning To Thrive In A Declining PCI Market: Long used to a growing market driven by favorable demographics, cardiovascular companies are facing a declining PCI market, in the US and Europe at least, and are being forced to shift their strategies to adapt. Volcano, for one, is articulating a new way to approach this declining market
|
Cassak, D.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|